ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing

This segment opens with foundational context on ALK-positive non-small cell lung cancer, establishing the clinical and scientific backdrop that makes this disease state — and its recent treatment advances — so compelling. Drs. Lovly and Shaw begin by addressing the epidemiology and prognosis associated with ALK-positive NSCLC, noting that while ALK rearrangements represent only approximately 4–5% of lung cancer cases, this still translates into a substantial global patient population. The discussion traces the dramatic evolution in outcomes over the nearly 20 years since ALK rearrangements were first identified in lung cancer in 2007 — from a disease with median survival of less than 12 months in the pre-targeted therapy era, to one where patients are now achieving unprecedented long-term disease control with modern ALK inhibitors.

The experts also take time to clarify the sometimes confusing nomenclature surrounding this biomarker — including terms such as ALK fusion, ALK rearrangement, ALK-positive, and ALK mutation — providing a practical reference point for a broad clinical audience.

The conversation then shifts to the critical question of biomarker testing: how often clinicians are testing for ALK in practice, and whether testing remains underutilized across community and academic settings. Drs. Lovly and Shaw emphasize that comprehensive genomic profiling is essential for all patients with NSCLC, as identifying actionable alterations like ALK rearrangements is the gateway to delivering highly effective, biomarker-directed therapies. They review available testing modalities — including liquid biopsy, next-generation sequencing of tumor tissue, and ALK immunohistochemistry — while underscoring the limitations of each approach and the importance of multidisciplinary collaboration with molecular pathologists to ensure accurate and timely results.